Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Apr 11, 2017 |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02333890 | A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer(CUBiC) | unknown | Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | completed | Phase 2 | 32 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | terminated | Phase 2 | 56 | Duke UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT00244881 | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT00952731 | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ | completed | Phase 2 | 27 | Northwestern UniversityOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT00132002 | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT02190227 | RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment | completed | Phase 2 | 30 | Jewish General HospitalOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT00100750 | Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | completed | Phase 2 | 41 | Russian Academy of Medical SciencesOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00068588 | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00079326 | Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00258349 | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00183963 | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00077376 | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT01329640 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | terminated | Phase 2 | 9 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00119262 | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | completed | Phase 2 | 226 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00559507 | Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2014 | clinicaltrials |
| NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy(DAFNE) | completed | Phase 2 | 65 | GBG Forschungs GmbHOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00006228 | Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00049114 | Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | terminated | Phase 2 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00429182 | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer | completed | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00005817 | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00024154 | Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098397 | FR901228 in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00045188 | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00017394 | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00095888 | 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer | terminated | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | terminated | Phase 2 | 29 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 11, 2012 | clinicaltrials |
| NCT00586326 | MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ(DCIS) | completed | Phase 2 | 133 | Hologic, Inc.INDUSTRY | 1 | Nov 6, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 11, 2017source: clinicaltrials